Загрузка...
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
BACKGROUND: Anti-tumor necrosis factor (anti-TNF) agents are an effective, but costly, treatment for spondyloarthritis (SpA). Worldwide, multiple sets of access criteria aim to restrict anti-TNF therapy to patients with specific clinical characteristics, yet the influence of access criteria on anti-...
Сохранить в:
| Опубликовано в: : | Cost Eff Resour Alloc |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5590198/ https://ncbi.nlm.nih.gov/pubmed/28904528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-017-0081-8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|